Filing identity and reporting period
Important identity discrepancy: The request identifies Tectonic Therapeutic, Inc., but the supplied Form 10-Q is for AVROBIO, Inc. (Nasdaq: AVRO), for the quarter ended March 31, 2019, filed May 13, 2019. The filing does not provide financial or operating information for Tectonic Therapeutic.
AVROBIO describes itself as a clinical-stage gene-therapy company developing ex vivo lentiviral therapies for rare diseases. It had no approved products and no product-sales revenue.
Financial results and liquidity
Amounts below are in U.S. dollars; financial-statement amounts are in millions unless stated otherwise.
| Metric | Q1 2019 | Q1 2018 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $12.446 | $5.647 |
| General and administrative expense | $5.254 | $2.141 |
| Total operating expenses / operating loss | $17.700 | $7.788 |
| Interest income | $0.657 | $0.158 |
| Net loss | $17.103 | $8.242 |
| Net loss per share, basic and diluted | $0.72 | $4.51 |
| Cash used in operating activities | $17.738 | $5.980 |
| Cash and cash equivalents at quarter-end | $108.476 | — |
At March 31, 2019, total assets were $117.368 million, total liabilities $10.580 million, and stockholders’ equity $106.788 million. Current assets were $113.679 million versus current liabilities of $9.935 million. The balance sheet reports no borrowings or other debt. Cash, cash equivalents and restricted cash totaled $108.968 million, including $0.492 million of restricted cash. Profit margins are not meaningful because the company had no revenue.
Management estimated that March 31 cash and cash equivalents would fund planned operating expenses and capital expenditures into the second half of 2020, subject to assumptions that could prove incorrect. The notes also state that existing cash, cash equivalents and marketable securities were expected to cover at least the next 12 months; the balance sheet lists cash and cash equivalents, while the MD&A runway estimate is into the second half of 2020. Management expects to need additional capital.
Material changes versus the prior comparable period
- Operating expenses increased $9.912 million, or about 127%, and net loss increased $8.861 million versus Q1 2018.
- R&D expense rose $6.799 million, driven by higher program costs in Fabry, Gaucher, Pompe and cystinosis, as well as personnel, preclinical, consulting and facility costs. G&A expense rose $3.113 million, including higher personnel and public-company legal and professional costs.
- Operating cash use rose to $17.738 million from $5.980 million. Investing cash use was $0.340 million; financing provided $0.252 million, mainly from stock-option exercises. Q1 2018 financing had included $58.263 million of net proceeds from preferred-stock issuance.
- Interest income increased by $0.499 million. Q1 2018 also included $0.587 million of expense from remeasurement of a derivative liability and $0.012 million of warrant remeasurement expense; neither liability remeasurement recurred in Q1 2019.
- Stock-based compensation increased to $1.455 million from $0.109 million. The accumulated deficit reached $88.842 million from $71.739 million at year-end 2018.
Outlook, developments and risks
- Clinical and regulatory: In April 2019, the FDA cleared the IND for AVR-RD-01. AVROBIO expected to open a U.S. site for its ongoing Phase 2 trial in the second half of 2019. It also reported April 2019 preclinical Gaucher-model results; these are not clinical efficacy results.
- Platform transition: The company planned to advance its plato platform, including the LV2 vector, closed automated manufacturing and a busulfan conditioning regimen with therapeutic drug monitoring. The filing cautions that comparability work, platform transition, manufacturing scale-up and the new conditioning approach could cause delays or safety issues; the plato platform had not yet been used to dose patients.
- Funding and commitments: AVROBIO expected expenses to rise as trials, manufacturing development, staffing and public-company costs expand. It may seek equity, debt, collaborations, licensing or other funding; such funding may be unavailable or dilute shareholders or require surrendering rights. A $2 million GenStem milestone for AVR-RD-04 would become due following treatment of the first patient in the planned Phase 1/2 cystinosis trial.
- Principal risks: Clinical failure or adverse events, patient recruitment, regulatory uncertainty, manufacturing and supplier dependence, competition, intellectual-property claims, and the need for additional capital. The company noted risks associated with gene therapy and conditioning, including potential serious adverse events.
- Controls and unusual events: Management concluded disclosure controls were ineffective as of March 31, 2019 because previously identified material weaknesses remained unremediated, including weaknesses in financial close, expense classification/accruals and cash-disbursement controls. A 2017 cyberattack resulted in theft of company funds; in February 2019, a vendor cyberattack led to payment of a fraudulent invoice. Management said remediation was ongoing. No material legal proceedings were reported.
- Other: The company reported no off-balance-sheet arrangements. It recorded $356,000 of Q1 2019 expense for laboratory sublease space provided by an entity affiliated with a board member.
Most important facts for investors to verify
- Confirm the intended issuer: the supplied filing is AVROBIO’s, not Tectonic Therapeutic’s.
- Review cash burn, the assumptions behind management’s runway into the second half of 2020, and the timing and terms of any future financing.
- Track AVR-RD-01 Phase 2 enrollment, the planned U.S. site opening, and subsequent clinical safety and efficacy disclosures.
- Assess whether the LV2/plato manufacturing transition and busulfan/TDM conditioning are implemented successfully and without material delay or safety concerns.
- Monitor remediation and independent validation of the disclosed material weaknesses, and any further cyber or payment-control incidents.
- Confirm the potential timing of the $2 million GenStem milestone and other license-related milestone, royalty and performance obligations.